Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 07/22 05:31:15 pm
82.35 CHF   +0.49%
07/22 NOVARTIS : IGI Securities Limited - Investor Kit
07/20DJBusiness Watch -- WSJ
07/19 NOVARTIS : Generic drug competition hits Novartis sales
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2012 | 01:16am CEST

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at marta.falconi@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
07/22 NOVARTIS : IGI Securities Limited - Investor Kit
07/21 NOVARTIS : Patent Issued for Compounds Containing S-N-Valeryl-N-{-Methyl)-Valine..
07/21 NOVARTIS : IGI Securities Limited - Investor Kit
07/20DJBusiness Watch -- WSJ
07/19 NOVARTIS : Generic drug competition hits Novartis sales
07/19 NOVARTIS : beats 2Q profit forecasts
07/19DJNOVARTIS : Warns on Profit as It Boosts Investment in Heart-Failure Pill Entrest..
07/19DJNOVARTIS : Says Profit Could Dip
07/19 NOVARTIS : 2Q net slips as generic drug competition hits sales
07/19DJNOVARTIS : Warns Profit Could Fall This Year Due to Increased Spending on Entres..
More news
Sector news : Pharmaceuticals - NEC
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/22 Biogen Needs To Fill Pipeline Or Rethink Strategy
07/21 Big Pharma Dominates Healthcare But Caregivers Are Top Sector Yield Dogs In J..
07/21 5 Key Messages From Novartis's Q2 Earnings Report You Shouldn't Miss
07/21 FDA Experts Back Brodalumab, With Warnings
07/21 NOVARTIS : On Road To Recovery?
Advertisement
Financials ($)
Sales 2016 48 867 M
EBIT 2016 11 412 M
Net income 2016 7 523 M
Debt 2016 14 038 M
Yield 2016 3,40%
P/E ratio 2016 24,24
P/E ratio 2017 22,00
EV / Sales 2016 4,78x
EV / Sales 2017 4,63x
Capitalization 219 526 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 90,0 $
Spread / Average Target 7,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-5.13%219 526
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
ROCHE HOLDING LTD.-9.62%218 832
MERCK & CO., INC.11.36%162 815
BRISTOL-MYERS SQUIBB C..10.02%126 333
More Results